Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Meghmani Organics Limited - Updates

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
M30 MGHOF 532865 MEGH

0
Meghmani Organics Limited - Shareholders meeting

2018-07-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
M30 MGHOF 532865 MEGH

0
Meghmani Organics Limited - AGM/Book Closure

2018-07-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
M30 MGHOF 532865 MEGH

22
Closing Bell: Banks, oil, infra stocks drag Sensex 273 pts; Nifty ends below 10,700 ahead of FO expiry

2018-06-27 moneycontrol
On the global front, Asian markets closed lower, led by the drop in Chinese stocks amid lingering trade worries. China's Shanghai Composite was down 1.11 percent and Hong Kong's Hang Seng shed 1.82 percent while Japan's Nikkei lost 0.3 percent.
JUBILANT 500325 JIPKY 533096 MGHOF HCTHY 530019 532712 512599 SYNDIBANK RCOM 506590 532281 PHILIPCARB BJJQY RLNIY ANNRY 532947 JETAIRWAYS IRB 532865 532622 JSWSTEEL BAJAJFINSV 532276 BAJFINANCE HCLTECH HCCC 532939 ADANIENT 500228 RELIANCE IDBI 532617 532978 IBRQY RIGD 500034 RPOWER 500116 IBN JPASSOCIAT 539207 532532 M30 ICICIBANK GDL 532174 ADANIPOWER MANPASAND MEGH

2
Meghmani Organics Limited - Investor Presentation

2018-05-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
M30 MGHOF 532865 MEGH

4
Market Live: Sensex at day#39;s high, Nifty reclaims 10,700; LT up 2% ahead of Q4 nos

2018-05-28 moneycontrol
Buzzing: Capacit’e Infraprojects share price rallied nearly 4 percent after Edelweiss Securities has initiated coverage with Buy rating on the stock and target price of Rs 397.
524715 INDIANB TORNTPHARM MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 GLKQY PRAJIND 532461 500850 INDHOTEL 500650 GLENMARK 522205 514043 INDIGO JETAIRWAYS 533023 532865 539207 TECHM 539448 M30 PNJZY 532296 TQRRY 500420 SUNPHARMA PNB WABCOINDIA EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex at day#39;s high, Nifty inches towards 10,700; LT up 2% ahead of Q4 nos

2018-05-28 moneycontrol
Market Update: The market is trading at day's high, with the Nifty inching towards 10,700 levels following sharp correction in crude oil prices and appreciation in the rupee.
524715 INDIANB MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 GLKQY PRAJIND 532461 500650 GLENMARK 522205 514043 INDIGO JETAIRWAYS 533023 532865 539207 TECHM 539448 M30 PNJZY 532296 SUNPHARMA PNB WABCOINDIA EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex strong, Midcap index up over 1%; Nifty IT underperforms

2018-05-28 moneycontrol
Market Update: The market continued to trade strong for the third consecutive day today, with the Sensex rising more than 150 points. Steep fall in crude oil prices and recovery in the rupee from 18-month low boosted investors sentiment.
524715 INDIANB MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 PRAJIND 532461 500650 522205 514043 INDIGO JETAIRWAYS 532865 539207 TECHM 539448 M30 PNJZY SUNPHARMA PNB EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex up 200 pts, Midcap extends gains; Manpasand Beverages dips 20%

2018-05-28 moneycontrol
Dr Reddy's Laboratories files lawsuit in US District Court: Shares of Dr Reddy's Laboratories rose 1.3 percent as company filed lawsuit in the United States District Court.
524715 INDIANB MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 PRAJIND 532461 500650 522205 514043 INDIGO JETAIRWAYS 532865 539207 TECHM 539448 M30 PNJZY SUNPHARMA PNB EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex reclaims 35K, opens up 100 pts; sharp fall in oil prices lift IOC, HPCL, BPCL

2018-05-28 moneycontrol
Rupee Update: The rupee strengthened by 39 paise to 67.39 against the dollar at the interbank forex market today on fresh selling of the greenback by exporters and banks.
522205 524715 INDIANB INDIGO 514043 MGHOF 532617 HIMATSEIDE 532814 JETAIRWAYS TCHQY 532865 532755 539448 TECHM PRAJIND M30 PNJZY 532461 SUNPHARMA PNB EXCELINDUS MEGH 500650

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

25m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

1h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...